These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23719260)

  • 1. Developing standards for breakthrough therapy designation in oncology.
    Horning SJ; Haber DA; Selig WK; Ivy SP; Roberts SA; Allen JD; Sigal EV; Sawyers CL
    Clin Cancer Res; 2013 Aug; 19(16):4297-304. PubMed ID: 23719260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Breakthrough Therapy Designation on Development Strategies and Timelines for Nononcology Drugs and Vaccines.
    Poirier AF; Murphy WR
    Clin Pharmacol Ther; 2016 Dec; 100(6):603-605. PubMed ID: 27513678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines.
    Hwang TJ; Franklin JM; Chen CT; Lauffenburger JC; Gyawali B; Kesselheim AS; Darrow JJ
    J Clin Oncol; 2018 Jun; 36(18):1805-1812. PubMed ID: 29688832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug development in serious diseases: the new "breakthrough therapy" designation.
    Woodcock J
    Clin Pharmacol Ther; 2014 May; 95(5):483-5. PubMed ID: 24747238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the Impact of US Food and Drug Administration Breakthrough Therapy Designation Timing on Trial Characteristics and Development Speed.
    Pregelj L; Hine DC; Kesselheim AS; Darrow JJ
    Clin Pharmacol Ther; 2021 Oct; 110(4):1018-1024. PubMed ID: 34048058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology.
    Kern KA
    J Oncol Pract; 2016 Aug; 12(8):e810-7. PubMed ID: 27460496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the breakthrough-therapy-designated drugs granted in China: A pooled analysis 2020-2022.
    Luo X; Qian F; Yang L; Li Y; Yang Y
    Drug Discov Today; 2022 Dec; 27(12):103370. PubMed ID: 36154876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakthrough Therapy Designation: Bringing Innovation Swiftly to Patients.
    Shah A
    Ther Innov Regul Sci; 2015 Mar; 49(2):256-261. PubMed ID: 30222423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated approval and breakthrough therapy designation: oncology drug development on speed?
    Yao JC; Meric-Bernstam F; Lee JJ; Eckhardt SG
    Clin Cancer Res; 2013 Aug; 19(16):4305-8. PubMed ID: 23833307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breakthrough Therapy Designation: CDER Analysis of Requests 4 Years Into the Program.
    Conrad R; Taylor K; Raggio M; Harrington A; Stark G; Kish A; Bertha A
    Ther Innov Regul Sci; 2017 Jul; 51(4):509-515. PubMed ID: 30227048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
    Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
    Eur J Health Econ; 2024 Aug; 25(6):979-997. PubMed ID: 37962724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacists' Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy Designation.
    Herink MC; Johnston K; Breninger K; Wu E; Irwin AN
    Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physician Perceptions of the FDA's Breakthrough Therapy Designation: An Update.
    Paquin RS; Boudewyns V; O'Donoghue AC; Aikin KJ
    Oncologist; 2022 Feb; 27(1):e85-e88. PubMed ID: 35305103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
    Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
    Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aligning US Agency Policies for Cardiovascular Devices Through the Breakthrough Devices Program.
    Moneer O; Rathi VK; Johnston JL; Ross JS; Dhruva SS
    JAMA Cardiol; 2023 Dec; 8(12):1174-1181. PubMed ID: 37878306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints.
    Kakkis ED; O'Donovan M; Cox G; Hayes M; Goodsaid F; Tandon PK; Furlong P; Boynton S; Bozic M; Orfali M; Thornton M
    Orphanet J Rare Dis; 2015 Feb; 10():16. PubMed ID: 25757705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breakthrough therapy-designated oncology drugs: are they rightfully criticized?
    Mulder J; Pasmooij AMG; Stoyanova-Beninska VV; Schellens JHM
    Drug Discov Today; 2020 Sep; 25(9):1580-1584. PubMed ID: 32562841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations.
    Daizadeh I
    Ther Innov Regul Sci; 2019 Mar; 53(2):264-269. PubMed ID: 29874936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.